CARIBOU BIOSCIENCES INC. - COMMON STOCK

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

25 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

03 Sep 2024 07:01:11 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

26 Aug 2024 15:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

12 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

09 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

02 Jun 2024 18:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

30 May 2024 15:01:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

07 May 2024 15:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 May 2024 15:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

15 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

04 Apr 2024 15:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

11 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

15 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

07 Jan 2024 10:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

12 Dec 2023 15:02:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

07 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire